Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database

BACKGROUND: Guidelines regarding the usage of adjuvant systemic therapy in patients with small human epidermal growth factor receptor 2 (HER2)-positive and estrogen receptor/progesterone receptor–positive (luminal HER2 positive) tumors are nonspecific. Outcomes of chemotherapy followed by endocrine...

Descripción completa

Detalles Bibliográficos
Autores principales: Nahleh, Zeina A, Elimimian, Elizabeth B, Elson, Leah C, Hobbs, Brian, Wei, Wei, Blake, Cassann N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412624/
https://www.ncbi.nlm.nih.gov/pubmed/32821110
http://dx.doi.org/10.1177/1178223420945694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412624/
https://www.ncbi.nlm.nih.gov/pubmed/32821110
http://dx.doi.org/10.1177/1178223420945694

Ejemplares similares